ChemoTech supports a Ukrainian hospital by selling an IQwave™ at a discounted price
After ChemoTech recently received a direct request for help from Ulis Hospital in Ukraine, the Company of course agreed to sell an IQwave™ to the hospital at a heavily discounted price.
The registration of ChemoTech's TSE system, also known as IQwave 3.0 CE, began in autumn 2021 in Ukraine. This process was completed just before Russia's invasion of the country began.
During the spring, the Company had ongoing contact with the distributor, who already had a complete launch strategy that had to be suspended due to the current war. Ulis Hospital played a central role in the distributor's launch strategy as it has a direct collaboration with the country's Ministry of Health and has long been a leading hospital in technology and innovation.
The order amounts to EUR 10,000.
“The fact that we have an ongoing war in Europe is terrible and we deeply empathize with the Ukrainian people who are bravely fighting to defend their homeland. We see it as a matter of course to do what we can to help. We see that ChemoTech's TSE technology can play a major role for cancer patients in Ukraine and this feels like an extra significant event.” - says Mohan Frick CEO and co-founder of ChemoTech
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
info@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation (TSE™), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
